<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(4)</volume><submitter>Riglet F</submitter><funding>Assistance Publique - Hôpitaux de Paris</funding><pubmed_abstract>&lt;h4>Background and objective&lt;/h4>Mycophenolate mofetil is widely used in kidney transplant recipients. Mycophenolate mofetil is hydrolysed by blood esterases to mycophenolic acid (MPA), the active drug. Although MPA therapeutic drug monitoring has been recommended to optimise the treatment efficacy by the area under the plasma concentration vs time curve, little is known regarding MPA concentrations in peripheral blood mononuclear cells, where MPA inhibits inosine monophosphate dehydrogenase. This study aimed to build a pharmacokinetic model using a population approach to describe MPA total and unbound concentrations in plasma and into peripheral blood mononuclear cells in 78 adult kidney transplant recipients receiving mycophenolate mofetil therapy combined with tacrolimus and prednisone.</pubmed_abstract><journal>Drugs in R&amp;D</journal><pagination>331-342</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7691413</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.</pubmed_title><pmcid>PMC7691413</pmcid><pubmed_authors>Riglet F</pubmed_authors><pubmed_authors>Benech H</pubmed_authors><pubmed_authors>Durrbach A</pubmed_authors><pubmed_authors>Verstuyft C</pubmed_authors><pubmed_authors>Barrail-Tran A</pubmed_authors><pubmed_authors>Michelon H</pubmed_authors><pubmed_authors>Bertrand J</pubmed_authors><pubmed_authors>Furlan V</pubmed_authors><pubmed_authors>Barau C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.</name><description>&lt;h4>Background and objective&lt;/h4>Mycophenolate mofetil is widely used in kidney transplant recipients. Mycophenolate mofetil is hydrolysed by blood esterases to mycophenolic acid (MPA), the active drug. Although MPA therapeutic drug monitoring has been recommended to optimise the treatment efficacy by the area under the plasma concentration vs time curve, little is known regarding MPA concentrations in peripheral blood mononuclear cells, where MPA inhibits inosine monophosphate dehydrogenase. This study aimed to build a pharmacokinetic model using a population approach to describe MPA total and unbound concentrations in plasma and into peripheral blood mononuclear cells in 78 adult kidney transplant recipients receiving mycophenolate mofetil therapy combined with tacrolimus and prednisone.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Dec</publication><modification>2026-05-03T22:13:22.477Z</modification><creation>2021-02-21T05:10:26Z</creation></dates><accession>S-EPMC7691413</accession><cross_references><pubmed>33025511</pubmed><doi>10.1007/s40268-020-00319-y</doi></cross_references></HashMap>